ImmunoGen (IMGN) Getting Somewhat Positive Media Coverage, Study Finds

News headlines about ImmunoGen (NASDAQ:IMGN) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ImmunoGen earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.2565501768137 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of analysts have commented on IMGN shares. Zacks Investment Research upgraded ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a research report on Tuesday, October 31st. Jefferies Group reiterated a “buy” rating and set a $9.00 target price on shares of ImmunoGen in a research report on Thursday, October 12th. Cantor Fitzgerald reiterated a “hold” rating and set a $5.00 target price on shares of ImmunoGen in a research report on Friday, November 3rd. Finally, BidaskClub upgraded ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $7.83.

ImmunoGen (NASDAQ:IMGN) opened at $8.03 on Friday. ImmunoGen has a 1-year low of $2.20 and a 1-year high of $8.84. The firm has a market capitalization of $1,061.97, a price-to-earnings ratio of -6.18 and a beta of 2.20. The company has a debt-to-equity ratio of -0.03, a current ratio of 2.81 and a quick ratio of 2.78.

ImmunoGen (NASDAQ:IMGN) last released its quarterly earnings results on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.42). The firm had revenue of $8.50 million during the quarter, compared to the consensus estimate of $26.09 million. During the same period last year, the business posted ($0.51) earnings per share. The firm’s revenue was up 10.4% on a year-over-year basis. equities research analysts anticipate that ImmunoGen will post -0.97 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3148898/immunogen-imgn-getting-somewhat-positive-media-coverage-study-finds.html.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Insider Buying and Selling by Quarter for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.